Ischemic Stroke as a Complication of Cryptococcal Meningitis and Immune Reconstitution Inflammatory Syndrome: a Case Report by Ellis, JP et al.
Ellis et al. BMC Infectious Diseases  (2018) 18:520 
https://doi.org/10.1186/s12879-018-3386-0CASE REPORT Open AccessIschemic stroke as a complication of
cryptococcal meningitis and immune
reconstitution inflammatory syndrome: a
case report
Jayne P. Ellis1,2* , Newton Kalata1, Elizabeth C. Joekes3, Samuel Kampondeni4, Laura A. Benjamin5,
Thomas S. Harrison6, David G. Lalloo7 and Robert S. Heyderman1,8*Abstract
Background: Cryptococcal meningitis remains the leading cause of adult meningitis in Sub-Saharan Africa. Immune
Reconstitution Inflammatory Syndrome (IRIS) following anti-retroviral therapy (ART) initiation is an important
complication. Here we report the first documented case of a IRIS reaction presenting as an ischemic stroke.
Case presentation: A 38 year old newly diagnosed HIV-infected, ART naive Malawian male presented to a tertiary
referral hospital in Blantyre, Malawi with a 2 week history of headache. A diagnosis of cryptococcal meningitis was
made and the patient was started on 1200 mg fluconazole once daily and flucytosine 25 mg/kg four times daily as
part of the Advancing Cryptococcal Treatment for Africa (ACTA) clinical trial. There was an initial clinical and
microbiological response to anti-fungal treatment and anti-retroviral therapy was started at week 4. The patient
re-presented 16 days later with recurrence of headache, fever, and a sudden onset of left sided weakness in the
context of rapid immune reconstitution; peripheral CD4 count had increased from a baseline of 29 cells/μl to 198
cells/μl. Recurrence of cryptococcal meningitis was excluded through CSF examination and fungal culture. Magnetic
Resonance Imaging (MRI) of the brain demonstrated multi-focal DWI (diffusion weighted imaging) positive lesions
consistent with an ischemic stroke. Given the temporal relationship to ART initiation, these MRI findings in the
context of sterile CSF with raised CSF protein and a rapid immune reconstitution, following an earlier favorable
response to treatment is most consistent with a paradoxical Immune Reconstitution Inflammatory Syndrome.
Conclusions: Stroke is an increasing cause of morbidity and mortality amongst HIV infected persons. Ischemic
stroke is a recognized complication of cryptococcal meningitis in the acute phase and is thought to be mediated
by an infectious vasculitis. This is the first time an ischemic stroke has been described as part of a paradoxical IRIS
reaction. This report adds to the spectrum of clinical IRIS presentations recognized and highlights to clinicians the
potential complications encountered at ART initiation in severely immunocompromised patients.
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Cryptococcal meningitis (CM) remains a common oppor-
tunistic infection in settings with high HIV prevalence and
is the leading cause of adult meningitis in Sub-Saharan
Africa [1]. Mortality remains high in Africa, ranging from
24% [2] to 100% [3] depending upon the anti-fungal regi-
men used. With roll out of anti-retroviral therapy (ART),
Immune Reconstitution Inflammatory Syndrome (IRIS)
has emerged as a prominent early complication in CM pa-
tients. Cryptococcal IRIS (C-IRIS) is believed to be caused
by the recovery of cryptococcus-specific immune responses
following ART initiation resulting in a pathological inflam-
matory response [4]. Two distinct forms of C-IRIS are
recognised: paradoxical and unmasking IRIS. Paradox-
ical IRIS is characterized by a clinical deterioration and
severe inflammation in a patient with previously diag-
nosed cryptococcal disease following ART initiation
despite an earlier favorable response to anti-fungal ther-
apy [4]. Paucity of viable organisms in the CSF despite se-
vere inflammation is characteristic of paradoxical C-IRIS
[5]. In contrast, unmasking IRIS is seen in patients with
sub-clinical/undiagnosed cryptococcosis presenting with
meningitis soon after ART initiation [4].
C-IRIS is therefore a highly heterogeneous condition
which may result in a variety of clinical syndromes with
both central nervous system (CNS) and non-CNS fea-
tures. CNS C-IRIS presentations reported in the literature
include: aseptic meningitis and intracranial cryptococco-
mas [6], spinal cord abscess [7], recalcitrant raised intra-
cranial pressure [8], optic nerve oedema [9] and cranial
nerve lesions [10]. Non-CNS manifestations of C-IRIS
include chorioretinitis [11], lymphadenitis [12], soft tissue
abscess, hypercalcaemia, cavitatory pulmonary disease
[13] and lobar pneumonitis [11].
Here we present the history of a Malawian man who de-
veloped an ischemic stroke in the context of a paradoxical
C-IRIS reaction. We aim to highlight the diagnostic
challenges encountered when a patient with known CM
presents with recurrence of symptoms and to add to
the literature describing the spectrum of clinical IRIS
presentations.
Case presentation
A 38 year old newly diagnosed HIV-infected, ART naive
Malawian male presented to Queen Elizabeth Central
Hospital, a large teaching hospital in Blantyre, Malawi. He
reported a 2 week history of headache and vomiting. He
had no past medical history of smoking, hypertension
or diabetes. On examination, his blood pressure was
122/80 mmHg, pulse 124 beats/min and temperature
36.7 °C. He had a Glasgow Coma Score (GCS) of 15/15,
there was evidence of meningism but no focal neurological
deficit. A lumbar puncture (Additional file 1: Table
S1) showed a WCC (white cell count) 6.0 × 106/μL,glucose < 2.22 mmol/L (normal range 2.22–4.44 mmol/L),
protein 1.68 g/L (normal range 0.15–0.45 g/L) and a
positive lateral flow assay for cryptococcal antigen (crAg;
IMMY, Norman, OK) (Additional file 1: Table S1).
Cerebrospinal fluid (CSF) opening pressure was 28 cm
H20 (normal range 5–20 cm H20). Quantitative crypto-
coccal culture (QCC) demonstrated 740,000 colony form-
ing units (cfu) /ml (normal < 0 cfu/ml). CD4 count at
admission was 29 cells/μl, Hb 11.6 g/dL, WCC 7.5 103/μL,
lymphocytes 0.9 103/μL. A diagnosis of CM was made and
the patient started on 1200 mg fluconazole once daily and
flucytosine 25 mg/kg four times daily as part of the
Advancing Cryptococcal Treatment for Africa (ACTA)
clinical trial (Open label, multicentre randomised trial;
trial no. ISRCTN45035509). The patient received 14 days
of treatment as an inpatient as per protocol. He required
twice daily lumbar punctures until day 7 to manage his
persistently raised intra-cranial pressure (ICP). His day 7
QCC was 22,300 cfu/ml and his QCC prior to discharge
on day 14 was 30 cfu/ml.
The patient re-presented 5 days post discharge with
recurrence of severe headaches, neck pain, drowsiness
and vomiting. On examination, he had a GCS (Glasgow
coma scale) of 15/15 and had no neurological deficit.
CSF opening pressure was 28 cm H20 and his CSF was
crAg positive, WCC 0 106/μL, glucose 2.88 mmol/L and
protein 1.22 g/L (Additional file 1: Table S1). The
patient was commenced on amphotericin to treat
suspected CM relapse whilst awaiting cryptococcal cul-
ture. The culture was subsequently negative and ampho-
tericin was discontinued. He continued on 800 mg
fluconazole once daily and was discharged 19 days later
with no ongoing symptoms of meningitis. ART was
started according to national guidelines (TDF/3TC/EFV)
at day 39.
The patient re-presented to hospital at day 54 (16 days
post ART commencement) with recurrence of headache
and fever, and a sudden onset of left sided weakness. He
reported adherence to his fluconazole and ART. On
examination, temperature was 38.2 °C, blood pressure
135/92 mmHg, pulse 89 beats/min, respiratory rate 22
breaths/min. He had a new left sided hemiparesis involv-
ing both the upper limb and lower limb (power 4/5
using the Medical Research Council (MRC) scale), and
there was no sensory deficit. The CSF opening pressure
was 21 cm H20. The CSF crAg remained positive, CSF
WCC 0 106/μL, CSF protein was high, 3.26 g/L. Culture
remained negative (Additional file 1: Table S1).
His peripheral CD4 count had increased from a base-
line of 29 cells/μl to 198 cells/μl. Magnetic Resonance
Imaging (MRI) of the brain (performed on day 5 of
symptom onset) demonstrated multi-focal DWI positive
lesions in the right corona radiata (Fig. 1), right posterior
limb of the internal capsule, right cerebral peduncle and
a c db
Fig. 1 a-d are MRI sequences taken on day 5 of an acute presentation of left arm and leg weakness; a-b are DWI axial B-900 sequences, showing
restriction in the right corona radiata (a) and posterior limb of the internal capsule (b). c and d (T2 axial sequences) showed high signal in the
corresponding areas to the DWI lesions; consistent with an acute ischemic stroke. High T2 signal was also seen in the left deep white matter (c);
Not shown but there was increased T2 signal (with DWI restricted diffusion) in the right cerebral peduncle and the brainstem (without DWI
changes); suggesting further ischaemia
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were consistent with an acute ischemic stroke. There
was high T2 signal without DWI restricted diffusion in
the right brainstem and left deep white matter, suggest-
ing previous ischemia. The MRI findings and raised CSF
protein in the context of rapid immune reconstitution,
following an earlier favorable clinical and microbio-
logical response to anti-fungal treatment and a sterile
CSF is consistent with paradoxical C-IRIS as opposed
to acute CM infection. Because of the involvement of
both anterior and posterior circulation, this met the
criteria for probable cerebral vasculitis12. The 0.35 T
GE MRI scanner used, does not support an ADC se-
quence. However, given the sudden onset of the
symptoms, these focal DWI changes, in the corre-
sponding anatomical location, occurring within a vas-
cular territory, the etiology is unlikely to be anything
other than vascular.
The development of an ischemic stroke was consid-
ered to be either a late manifestation of the CM infec-
tion or due to intensification of HIV- or CM- associated
inflammation with immune reconstitution8. Fluconazole
at a dose of 400 mg was continued with ART and the
patient achieved good functional improvement. Cortico-
steroids were not given.a b c
Fig. 2 a-e are MRI sequences taken 1 month later from symptom onset an
new DWI lesion (b – arrow) suggesting evolving inflammation. However, th
(T2 axial) shows maturation of previously reported infarctAn MRI scan performed one month later demon-
strated maturation of the ischemic stroke (Fig. 2), and a
new DWI lesion in the right caudate, consistent with
C-IRIS. The patient however reported complete reso-
lution of the left sided weakness and remained well at
day 185.
Discussion and conclusions
This case demonstrates the diagnostic challenges en-
countered when a patient with known CM presents with
recurrence of symptoms following commencement of
ART. Paradoxical C-IRIS complicates around 15% of
cases of CM in ART naïve patients [14], usually during
the first ten months of ART [4]. There is no definitive
diagnostic test for IRIS but by adopting the clinical cri-
teria checklist approach set out by the International
Network for the Study of HIV-associated IRIS [4]
(Additional file 1: Table S2), we were able to diagnose
paradoxical C-IRIS in this low resource setting. This
patient had several of the recognized risk factors for
paradoxical IRIS including: low CD4 count at ART initi-
ation, high fungal burden [15] and lack of initial CSF inflam-
mation (WBC< 25 cells/μl and CSF protein < 50 mg/dL)
[16]. These characteristics are not uncommon in pa-
tients with CM in Sub-Saharan Africa.d e
d on the background of a resolved left sided weakness. a-b; shows a
e burden of the previous DWI changes reported in (1) is less. c-d
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patient was not commenced until after week 4 of treat-
ment, and was continued despite the diagnosis of para-
doxical C-IRIS [17]. Although the reported mortality risk
associated with C-IRIS is highly variable (0–83% [4]), ART
and successful immune reconstitution is key to survival in
HIV and so ART was not interrupted or discontinued due
to IRIS. For non-life threatening IRIS manifestations, there
are no specific definitive treatments recommended and
symptoms should resolve spontaneously within weeks to
months. For deteriorating patients with CNS inflamma-
tion leading to raised intra-cranial pressure, with no alter-
native diagnosis, corticosteroids should be considered
(0.5 mg – 1.0 mg/kg per day of prednisolone) [17]. As our
patient was clinically stable with improving neurology,
steroids were not given.
Ischemic stroke is a recognized complication of CM in
the acute phase and is thought to be mediated by an infec-
tious vasculitis, primarily causing an endarteritis obliterans
[18]. In this case however, the progressive parenchymal
disease in the presence of sterile CSF and absence of trad-
itional vascular risk factors, is most consistent with an
immuno-pathological process. The increased risk of cere-
brovascular disease in patients with HIV is well docu-
mented [19]. The pathophysiology is likely multifactorial
with proposed mechanisms including increased prevalence
of traditional vascular risk factors, infectious vasculitis,
HIV-associated vasculopathy, and coagulopathy [20]. In a
case-control study of 222 Malawian adults with MRI con-
firmed acute stroke, the highest risk of stroke in patients
with untreated HIV infection was in the first 6 months
after starting antiretroviral therapy (ART) (aOR 15.6
[4.21–46.6], p < 0.001) [19]. These results have led to
the hypothesis that IRIS may be contributing to the disease.
In conclusion, this case report adds to the spectrum of
clinical IRIS presentations encountered while managing
CM. Whilst ART is essential in improving survival out-
comes in these patients, clinicians should be aware of
the complications of ART initiation including C-IRIS
and stroke.
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